The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

Medically reviewed by Susan Bard, MD Menopause is a time of significant change, and skin changes are common. You may have ...

People with moderate to severe eczema may receive biologics when ... Another class of medications called Janus kinase (JAK) inhibitors, which are small molecules that block signaling pathways ...

Opens in a new tab or window ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting topical ruxolitinib (Opzelura ...

Robert Sidbury MD, MPH explored the “long list” of treatment options in atopic dermatitis and how the treatment landscape has changed as a result in a video interview with Healio.“So long list – I ...

A subset of patients treated with delgocitinib cream 20 mg/g for moderate to severe chronic hand eczema achieved a ...

Eczema is an umbrella term for a group of ... risk since they don’t suppress the entire immune system. Oral JAK inhibitors. JAK (janus kinase) inhibitors, such as abrocitinib (Cibinqo) and ...

Eczema, also known as atopic dermatitis, is a common cause of dermatitis and affects 10 to 30% of children and 2 to 10% of adults each year in the United States. Topical steroids—specifically ...

PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

As Incyte strives to push its topical JAK inhibitor Opzelura into additional ... currently approved in atopic dermatitis, also known as eczema, as well as vitiligo. Looking ahead, Incyte expects ...